Compare AGIO & ABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | ABR |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | 653 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2013 | N/A |
| Metric | AGIO | ABR |
|---|---|---|
| Price | $30.08 | $7.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $37.63 | $10.30 |
| AVG Volume (30 Days) | 623.7K | ★ 4.1M |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 16.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $71.05 | N/A |
| Revenue Next Year | $163.65 | N/A |
| P/E Ratio | ★ N/A | $9.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $7.11 |
| 52 Week High | $46.00 | $12.58 |
| Indicator | AGIO | ABR |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 45.32 |
| Support Level | $26.48 | $7.23 |
| Resistance Level | $30.90 | $8.07 |
| Average True Range (ATR) | 0.97 | 0.25 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 98.65 | 17.82 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.